Literature DB >> 22402885

VEGF, PF4 and PDGF are elevated in platelets of colorectal cancer patients.

Jon E Peterson1, David Zurakowski, Joseph E Italiano, Lea V Michel, Susan Connors, Marsha Oenick, Robert J D'Amato, Giannoula L Klement, Judah Folkman.   

Abstract

Platelets sequester angiogenesis regulatory proteins which suggests an avenue for developing biomarkers to monitor disease. We describe a comparison of angiogenesis regulatory proteins found in platelets of colorectal cancer patients and normal controls. Platelet and plasma content of vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), platelet derived growth factor (PDGF), platelet factor 4 (PF4), thrombospondin-1 (TSP-1) and endostatin in 35 patients with colon cancer were compared with 84 age-matched healthy controls using ELISAs. We standardized the platelet preparation procedure, introduced process controls and normalized the respective protein levels to platelet numbers using an actin ELISA. Statistically significant differences were found in the median levels of VEGF, PF4 and PDGF in platelets of patients with cancer compared to healthy individuals. Platelet concentrations in cancer patients versus controls were: VEGF 1.3 versus 0.6 pg/10(6), PF4 18.5 versus 9.4 ng/10(6), and PDGF 34.1 versus 21.0 pg/10(6). Multivariable logistic regression analysis indicated that PDGF, PF4 and VEGF were independent predictors of colorectal carcinoma and as a set provided statistically significant discrimination (area under the curve = 0.893, P < .0001). No significant differences were detected for bFGF, endostatin, or TSP-1. Reference Change Value analysis determined that the differences seen were not clinically significant. Plasma levels yielded no correlations.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22402885     DOI: 10.1007/s10456-012-9259-z

Source DB:  PubMed          Journal:  Angiogenesis        ISSN: 0969-6970            Impact factor:   9.596


  82 in total

Review 1.  Nanoparticle Probes for the Detection of Cancer Biomarkers, Cells, and Tissues by Fluorescence.

Authors:  Alyssa B Chinen; Chenxia M Guan; Jennifer R Ferrer; Stacey N Barnaby; Timothy J Merkel; Chad A Mirkin
Journal:  Chem Rev       Date:  2015-08-27       Impact factor: 60.622

2.  Prognostic role of pretreatment platelet/lymphocyte ratio in patients with non-small cell lung cancer.

Authors:  Mehmet Kos; Cemil Hocazade; F Tugba Kos; Dogan Uncu; Esra Karakas; Mutlu Dogan; Hikmet Gulsen Uncu; Nuriye Yildirim; Nurullah Zengin
Journal:  Wien Klin Wochenschr       Date:  2015-02-27       Impact factor: 1.704

3.  Platelet-mediated angiogenesis is independent of VEGF and fully inhibited by aspirin.

Authors:  J Etulain; C Fondevila; S Negrotto; M Schattner
Journal:  Br J Pharmacol       Date:  2013-09       Impact factor: 8.739

4.  Circulatory TGF-beta1 is significantly higher in early stage of pulmonary sarcoidosis.

Authors:  Mehdi Mirsaeidi; Hesham R Omar; Andrew Calzadilla; Ahmad El Khatib; Philip Whitney; Nadera Sweiss; Daniel Culver; Michael Campos; Robert Baughman; Roberto Machado
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2018-04-28       Impact factor: 0.670

Review 5.  Microenvironmental regulation of tumour angiogenesis.

Authors:  Michele De Palma; Daniela Biziato; Tatiana V Petrova
Journal:  Nat Rev Cancer       Date:  2017-07-14       Impact factor: 60.716

6.  Prognostic effects of preoperative obstructive pneumonitis or atelectasis and comparison with tumor size in non-small cell lung cancer.

Authors:  Zhaofei Pang; Nan Ding; Wei Dong; Yang Ni; Tiehong Zhang; Xiao Qu; Jiajun Du; Qi Liu
Journal:  J Thorac Dis       Date:  2017-03       Impact factor: 2.895

7.  CXCL4 mediates tumor regrowth after chemotherapy by suppression of antitumor immunity.

Authors:  Yang Zhang; Jing Gao; Xia Wang; Shaorong Deng; Hao Ye; Wen Guan; Mingyuan Wu; Shunying Zhu; Yan Yu; Wei Han
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

8.  Platelet VEGF and serum TGF-β1 levels predict chemotherapy response in non-small cell lung cancer patients.

Authors:  Bao-Hong Fu; Zhan-Zhao Fu; Wei Meng; Tao Gu; Xiao-Dong Sun; Zhi Zhang
Journal:  Tumour Biol       Date:  2015-03-29

9.  Thrombocytosis and hepatocellular carcinoma.

Authors:  Brian I Carr; Vito Guerra
Journal:  Dig Dis Sci       Date:  2013-01-12       Impact factor: 3.199

Review 10.  The prothrombotic activity of cancer cells in the circulation.

Authors:  Annachiara Mitrugno; Garth W Tormoen; Peter Kuhn; Owen J T McCarty
Journal:  Blood Rev       Date:  2015-07-14       Impact factor: 8.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.